Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VBI-2902
- Development stage
- Phase 1
- Lead developer
- VBI Vaccines
- Modality
- Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
VBI-2902 is a monovalent COVID-19 vaccine candidate developed by VBI Vaccines. It is based on an enveloped virus-like particle (eVLP) platform and expresses a modified prefusion form of the SARS-CoV-2 spike protein. The vaccine is formulated with an aluminum phosphate adjuvant and delivered via intramuscular injection. Preclinical and clinical studies have shown that VBI-2902 induces strong and durable neutralizing antibody responses, with titers exceeding those found in convalescent sera, as well as robust T cell responses. The vaccine has demonstrated broad reactivity against multiple SARS-CoV-2 variants in animal models and was well-tolerated in human trials without significant safety signals[1][3][4][5][6][7]. Developed in collaboration with the National Research Council of Canada, it has been evaluated in Phase 1/2 clinical trials for the prevention of COVID-19.
- Other names
- StealthX SARS-CoV-2 vaccineVBI eVLP COVID-19 vaccineStealthX COVID-19 vaccine
02
Targets
SARS-CoV-2 spike
Beyond the preview
Go deeper on VBI-2902.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VBI-2902.